Ionclinics

Ionclinics is a leading company in cerebral neuromodulation with an international scope. Since its foundation in 2012, the company has been pioneering high-tech solutions in the field. Ionclinics' core focus revolves around the development, manufacturing, distribution, and commercialization of medical devices that significantly improve patients' neuroplasticity, leading to a remarkable increase in their quality of life without pain or adverse effects. The company's neuromodulation technology finds clinical applications in critical disciplines such as psychiatry, psychology, neurology, and rehabilitation, addressing associated pathologies including but not limited to depression, neuropathic pain, fibromyalgia, migraine, OCD, addiction, Parkinson's, stroke, and schizophrenia. Ionclinics has been recognized and supported by the public sector through innovative projects acknowledged by the Valencian Agency of Innovation (AVI) and the Center for Technological Development and Innovation (CDTI), with funding from European sources. Their most recent grant from CDTI is a testament to their commitment to innovation, enabling the historic step of bringing cerebral neuromodulation techniques to homes without the need for in-person medical intervention. This achievement, made possible through their continuous research and development efforts supplemented by artificial intelligence protocols, signifies a pioneering advancement in the industry. Based in Spain, Ionclinics represents a promising investment opportunity as it continues to push the boundaries of medical technology, making a substantial impact on patient care and the healthcare landscape as a whole.